650 related articles for article (PubMed ID: 18259679)
1. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of osteoblast function in vitro by aminobisphosphonates.
Orriss IR; Key ML; Colston KW; Arnett TR
J Cell Biochem; 2009 Jan; 106(1):109-18. PubMed ID: 19003973
[TBL] [Abstract][Full Text] [Related]
3. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
4. Osteoblast proliferation and maturation by bisphosphonates.
Im GI; Qureshi SA; Kenney J; Rubash HE; Shanbhag AS
Biomaterials; 2004 Aug; 25(18):4105-15. PubMed ID: 15046901
[TBL] [Abstract][Full Text] [Related]
5. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
6. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
[TBL] [Abstract][Full Text] [Related]
8. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model.
Komatsu K; Shimada A; Shibata T; Wada S; Ideno H; Nakashima K; Amizuka N; Noda M; Nifuji A
J Endocrinol; 2013 Nov; 219(2):145-58. PubMed ID: 24096963
[TBL] [Abstract][Full Text] [Related]
9. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization.
Brandao-Burch A; Utting JC; Orriss IR; Arnett TR
Calcif Tissue Int; 2005 Sep; 77(3):167-74. PubMed ID: 16075362
[TBL] [Abstract][Full Text] [Related]
10. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Gangoiti MV; Cortizo AM; Arnol V; Felice JI; McCarthy AD
Eur J Pharmacol; 2008 Dec; 600(1-3):140-7. PubMed ID: 18973752
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents.
Singh US; Shankar R; Kumar A; Trivedi R; Chattopadhyay N; Shakya N; Palne S; Gupta S; Hajela K
Bioorg Med Chem; 2008 Sep; 16(18):8482-91. PubMed ID: 18752963
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
Idris AI; Greig IR; Bassonga-Landao E; Ralston SH; van 't Hof RJ
Endocrinology; 2009 Jan; 150(1):5-13. PubMed ID: 18772231
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
14. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
Schindeler A; Little DG
Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures.
Luppen CA; Smith E; Spevak L; Boskey AL; Frenkel B
J Bone Miner Res; 2003 Jul; 18(7):1186-97. PubMed ID: 12854828
[TBL] [Abstract][Full Text] [Related]
16. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors.
Klein BY; Ben-Bassat H; Breuer E; Solomon V; Golomb G
J Cell Biochem; 1998 Feb; 68(2):186-94. PubMed ID: 9443074
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
18. 2010 Young Investigator Award winner: Therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization.
Schoenecker J; Mignemi N; Stutz C; Liu Q; Edwards J; Lynch C; Holt G; Schwartz H; Mencio G; Hamm H
Spine (Phila Pa 1976); 2010 Apr; 35(9):1008-16. PubMed ID: 20407341
[TBL] [Abstract][Full Text] [Related]
19. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
Idris AI; Landao-Bassonga E; Ralston SH
Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
